Tuesday, Santarus Inc. (SNTS) said the U.S. Food and Drug Administration or FDA approved Schering-Plough HealthCare Products, Inc.'s, New Drug Application or NDA for ZEGERID OTC Capsules with a dosage strength of 20 mg of omeprazole for over-the-counter treatment of frequent heartburn. Schering-Plough and Merck & Co., Inc. merged on November 3, 2009.
The NDA was submitted by Schering-Plough under the terms of a license agreement for OTC proton pump inhibitor or PPI products using Santarus' proprietary technology. Upon approval of ZEGERID OTC, Santarus earned a $20 million milestone and may be entitled to receive up to an additional $37.5 million in sales milestones. Santarus will also be entitled to a low double-digit royalty, subject to adjustment in certain circumstances, on net sales of any ZEGERID OTC products sold by Schering-Plough HealthCare Products under the license agreement. In turn, Santarus will be obligated to pay royalties to the University of Missouri on net sales of any such OTC products.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.